Ovid Therapeutics, Inc. is hitting the pause button on its program to develop OV101 (gaboxadol) for Angelman syndrome following the failure of the Phase III NEPTUNE trial. The company plans a full analysis of trial data and further discussions with the US Food and Drug Administration.
OV101 was Ovid's lead asset, but now the company will turn its attention to OV935 (soticlestat) in Dravet syndrome and...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
